grant
Mitogenic and Oncogenic Regulation of ERK/RSK Signaling
Organization WEILL MEDICAL COLL OF CORNELL UNIVLocation NEW YORK, UNITED STATESPosted 8 Feb 1988Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2025Applications GrantsAreaAutomobile DrivingAutophagosomeBasal Transcription FactorBasal transcription factor genesBasic ResearchBasic ScienceBehaviorBindingBinding SitesBiochemicalBiologicalBiological FunctionBiological MarkersBiological ProcessBiologyBreastCancer TreatmentCancersCarcinomaCause of DeathCell BodyCell Communication and SignalingCell Growth in NumberCell MultiplicationCell ProliferationCell SignalingCell membraneCellsCellular ProliferationCessation of lifeChaperoneCharacteristicsChemoresistanceChromatinClinicalCombining SiteCommunitiesCommunity DevelopmentsComplexCytoplasmic MembraneDNA mutationDataDeathDevelopmentDiseaseDisorderDisseminated Malignant NeoplasmDockingDrug TargetingDrug TherapyDrug resistanceERK 2ERK MAP KinasesERK2ERT1Early identificationEnvironmentEpithelial CellsEpithelial cancerEventExtracellular Signal Regulated KinasesExtracellular Signal-Regulated Kinase 2Extracellular Signal-Regulated MAP KinasesGene Down-RegulationGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenesGeneticGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGoalsGrantGrant ProposalsGrowthHistone H3Histone H3.3HistonesImmune mediated therapyImmunologically Directed TherapyImmunotherapyIn VitroIntermediary MetabolismIntracellular Communication and SignalingInvadedInvestigationIsoformsLaboratoriesLinkLocationLungLung Respiratory SystemLysosomesMAP Kinase 1MAP Kinase 2MAPK ERK KinasesMAPK1MAPK1 Mitogen-Activated Protein KinaseMAPK1 geneMAPK2MAPK2 Mitogen-Activated Protein KinaseMEKsMaintenanceMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMediatingMedicalMembraneMembrane Transport ProteinsMembrane TransportersMesenchymalMetabolicMetabolic ProcessesMetabolismMetastasisMetastasizeMetastatic CancerMetastatic LesionMetastatic Malignant NeoplasmMetastatic MassMetastatic NeoplasmMetastatic TumorMitogen Activated Protein Kinase 1Mitogen-Activated Protein Kinase 2ModificationMolecularMolecular ChaperonesMolecular InteractionMotilityMutationNeoplasm MetastasisNutrientOncogenicOncologyOncology CancerOperative ProceduresOperative Surgical ProceduresOutcomeP41MAPKP42MAPKPRKM1PRKM2Pathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPharmacological TreatmentPharmacotherapyPhasePhenotypePlasma MembranePlayPositionPositioning AttributePrevalencePreventionPrimary NeoplasmPrimary TumorProcessProliferatingPropertyProtein IsoformsProteomicsRNA ExpressionRas/RafReactive SiteRegulationRoleSP1SP1 geneSecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSupporting CellSurgicalSurgical InterventionsSurgical ProcedureSystemTherapeuticTherapeutic InterventionThreonine/Tyrosine Protein KinaseTimeTissue GrowthToxic effectToxicitiesTranscriptionTranscription Factor Proto-OncogeneTranscription Factor Sp1 GeneTranscription RepressionTranscription factor genesTumor CellUpregulationVariantVariationWorkanti-cancer therapybio-markersbiologicbiologic markerbiological signal transductionbiomarkerbiomarker developmentbiomarker identificationcancer initiationcancer metastasiscancer progenitorcancer progenitor cellscancer progressioncancer stem cellcancer stem like cellcancer therapycancer-directed therapychemoresistantchemotherapy resistancechemotherapy resistantchromatin assembly factor 1chromatin assembly factor Ichromatin remodelingdevelop drug resistancedevelopmentaldifferential expressiondifferentially expresseddrivingdrug developmentdrug discoverydrug interventiondrug resistance developmentdrug resistantdrug treatmentepithelial carcinomaepithelial to mesenchymal transitionexpectationextracellular signal related kinasefightinggene repressiongenetic approachgenetic strategygenome mutationidentification of biomarkersidentification of new biomarkersimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedin vivoindividualized therapeuticinnovateinnovationinnovativeinsightinterestintervention therapylysosome membranemalignancymalignant progenitormalignant stem cellmarker identificationmembrane structuremetabolism measurementmetabolomicsmetabonomicsmetastatic processmortalityneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoncogenic progenitoroncogenic stem cellsontogenyp42 MAP Kinasep42 MAPKpathwaypatient oriented outcomespersonalized therapeuticpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsplasmalemmapredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreventpreventingprogenitor like cancer cellprogramspromoterpromotorresistance to Drugresistant to Drugresponse to therapyresponse to treatmentsmall moleculesocial rolestem like cancer cellsuccesssurgerytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy responsetraffickingtranscription factortranscriptional differencestranscriptional reprogrammingtranscriptomicstransdifferentiationtreatment responsetreatment responsivenesstumor cell metastasistumor growthtumor progressiontumorigenic
Description preview
Cancer is the 2nd leading cause of death in the US. The advent of new treatments such as immunotherapy and
targeted therapies have revolutionized the fight against cancer, and when combined with surgery, often result in
significant positive therapeutic responses. Unfortunately, some tumor cells gain the ability to resist drug- and
immune-…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click